Log in

NASDAQ:CELGCelgene Stock Price, Forecast & News

$108.24
0.00 (0.00 %)
(As of 11/22/2019)
Add
Compare
Today's Range
$108.24
Now: $108.24
$108.24
50-Day Range
$108.24
MA: $108.24
$108.24
52-Week Range
$58.59
Now: $108.24
$110.70
Volume114,302 shs
Average Volume6.77 million shs
Market Capitalization$77.04 billion
P/E Ratio14.22
Dividend YieldN/A
Beta1.41
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers. The company's products also include IDHIFA for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (rrAML) with an isocitrate dehydrogenase-2 mutation; VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and AML; THALOMID to treat patients with MM; and ISTODAX, an epigenetic modifier. Its preclinical and clinical-stage product candidates include small molecules, biologics, and cell therapies for immune-inflammatory diseases, myeloid diseases, epigenetics, protein homeostasis, and immuno-oncology. The company has agreements with BeiGene, Ltd; Acceleron Pharma, Inc.; Agios Pharmaceuticals, Inc.; bluebird bio, Inc.; Lycera Corp.; Juno Therapeutics, Inc.; and EXSCIENTIA LTD. Celgene Corporation was founded in 1980 and is headquartered in Summit, New Jersey.
Read More
Celgene logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.0Community Rank: 3.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 3.1 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.75 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:CELG
CUSIP15102010
Phone908-673-9000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$15.28 billion
Cash Flow$8.88 per share
Book Value$16.98 per share

Profitability

Net Income$4.05 billion

Miscellaneous

Employees8,852
Market Cap$77.04 billion
Next Earnings DateN/A
OptionableOptionable
$108.24
0.00 (0.00 %)
(As of 11/22/2019)
30 days | 90 days | 365 days | Advanced Chart

Receive CELG News and Ratings via Email

Sign-up to receive the latest news and ratings for CELG and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Celgene (NASDAQ:CELG) Frequently Asked Questions

How has Celgene's stock price been impacted by Coronavirus (COVID-19)?

Celgene's stock was trading at $108.24 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CELG stock has increased by 0.0% and is now trading at $108.24.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Celgene?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Celgene in the last year. There are currently 5 hold ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Celgene
.

How were Celgene's earnings last quarter?

Celgene Co. (NASDAQ:CELG) announced its quarterly earnings results on Thursday, October, 31st. The biopharmaceutical company reported $2.99 earnings per share for the quarter, topping the Zacks' consensus estimate of $2.70 by $0.29. The biopharmaceutical company earned $4.52 billion during the quarter, compared to analysts' expectations of $4.39 billion. Celgene had a net margin of 34.63% and a return on equity of 78.15%. Celgene's revenue was up 16.1% compared to the same quarter last year. During the same period last year, the firm earned $2.29 EPS.
View Celgene's earnings history
.

When did Celgene's stock split? How did Celgene's stock split work?

Celgene's stock split before market open on Thursday, June 26th 2014. The 2-1 split was announced on Thursday, June 19th 2014. The newly minted shares were payable to shareholders after the closing bell on Wednesday, June 25th 2014. An investor that had 100 shares of Celgene stock prior to the split would have 200 shares after the split.

What price target have analysts set for CELG?

5 brokerages have issued 12-month price objectives for Celgene's shares. Their forecasts range from $100.00 to $115.00. On average, they expect Celgene's share price to reach $106.50 in the next year. This suggests that the stock has a possible downside of 1.6%.
View analysts' price targets for Celgene
.

Has Celgene been receiving favorable news coverage?

Media stories about CELG stock have trended negative recently, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Celgene earned a news sentiment score of -2.4 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days.
View the latest news about Celgene
.

Who are some of Celgene's key competitors?

What other stocks do shareholders of Celgene own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Celgene investors own include Akorn (AKRX), Gilead Sciences (GILD), Skechers USA (SKX), NVIDIA (NVDA), Bank of America (BAC), Integrated Device Technology (IDTI), Alibaba Group (BABA), Netflix (NFLX), Micron Technology (MU) and Intel (INTC).

Who are Celgene's key executives?

Celgene's management team includes the following people:
  • Mr. Mark J. Alles, Chairman & CEO (Age 60)
  • Mr. David V. Elkins, Exec. VP & CFO (Age 50)
  • Mr. Peter N. Kellogg, Exec. VP & Chief Corp. Strategy Officer (Age 63)
  • Dr. S. J. Rupert Vessey MA, BM BCh, FRCP, DPhil, Pres of Research & Early Devel. (Age 54)
  • Dr. Alise Reicin M.D., Pres of Global Clinical Devel. (Age 58)

What is Celgene's stock symbol?

Celgene trades on the NASDAQ under the ticker symbol "CELG."

Who are Celgene's major shareholders?

Celgene's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include TCF National Bank (0.00%). Company insiders that own Celgene stock include Ernest Mario, James J Loughlin and Terrie Curran.
View institutional ownership trends for Celgene
.

Which major investors are buying Celgene stock?

CELG stock was acquired by a variety of institutional investors in the last quarter, including TCF National Bank.
View insider buying and selling activity for Celgene
.

How do I buy shares of Celgene?

Shares of CELG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Celgene's stock price today?

One share of CELG stock can currently be purchased for approximately $108.24.

How big of a company is Celgene?

Celgene has a market capitalization of $77.04 billion and generates $15.28 billion in revenue each year. The biopharmaceutical company earns $4.05 billion in net income (profit) each year or $7.61 on an earnings per share basis. Celgene employs 8,852 workers across the globe.

What is Celgene's official website?

The official website for Celgene is www.celgene.com.

How can I contact Celgene?

Celgene's mailing address is 86 MORRIS AVENUE, SUMMIT NJ, 07901. The biopharmaceutical company can be reached via phone at 908-673-9000 or via email at [email protected]

This page was last updated on 8/14/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.